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Trachoma is the most common infectious cause of blindness and a major public health problem inmany developing countries. It
is caused by recurrent ocular infection with Chlamydia trachomatis in childhood, with conjunctival scarring seen later in life.
The pathogenesis of trachomatous scarring, however, is poorly understood, and this study was carried out to investigate the im-
munofibrogenic correlates of trachomatous conjunctival scarring. A case-control study of 363 cases with conjunctival scarring
and 363 control participants was conducted. Investigations included in vivo confocal microscopy (IVCM) assessment, quantita-
tive real-time PCR gene expression, C. trachomatis detection, and nonchlamydial bacterial culture. Trachomatous scarring was
found to be strongly associated with a proinflammatory, innate immune response with increased expression of psoriasin,
interleukin-1, tumor necrosis factor alpha, defensin-4A, chemokine ligand 5, and serum amyloid A1. There was also differen-
tial expression of various modifiers of the extracellular matrix, including metalloproteinases 7, 9, 10, and 12, tissue inhibitor of
matrix metalloproteinase 1, and secreted protein acidic cystein-rich-like 1. The expression of many of these genes was also signif-
icantly associated with the presence of nonchlamydial bacterial infection. These infections had a marked effect on conjunctival
immune processes, including an increased inflammatory infiltrate and edema seen with IVCM. This study supports the possibil-
ity that the immunofibrogenic response in scarring trachoma is partly stimulated by nonchlamydial bacterial infection, which is
characterized by the expression of innate factors.
Trachoma is amajor cause of blindness, especially in developingcountries. Children suffer recurrent episodes of ocular infec-
tionwithChlamydia trachomatis, which stimulates a follicular and
papillary conjunctivitis. These children are subsequently at risk of
developing conjunctival scarring,which canprogress to entropion
(in-turning of the eyelid) and trichiasis (eyelashes rubbing against
the eyeball). Corneal opacity and blindness can result, as well as
severe and persistent discomfort. Trachoma is the most common
infectious cause of blindness, with at least 1.3 million people esti-
mated to be blind from the disease, 8.2 million to have trichiasis,
and 40 million to have active disease (40, 52).
The pathogenesis of trachoma, and especially of the scarring
process, is poorly understood. Histological studies of conjunctival
biopsy specimens from scarred individuals show a chronic inflam-
matory cell infiltrate, especially in the substantia propria, with
large numbers of lymphocytes (1, 4, 25, 51). T cells, both CD4
and CD8, tend to outnumber B cells. The conjunctival stroma is
replaced by thick, mostly avascular scar tissue. Earlier studies ex-
amining lymphoproliferative responses to chlamydial antigens in
trachomatous subjects were consistent with findings from animal
models of infection, which suggested that a strong Th1 response
with production of gamma interferon (IFN-) was important in
clearing chlamydial infection and may be protective against the
development of scarring (5, 27, 28). These studies also provided
limited evidence that Th2 responses were associated with con-
junctival fibrosis, which may have parallels with other infectious
diseases, such as schistosomiasis (59). However, recent studies
usingmicroarray analysis of conjunctival swab samples from sub-
jects with trachomatous trichiasis have not found evidence of
Th1/Th2 polarization. Instead, proinflammatory mediators, par-
ticularly suggestive of innate immune responses and factors affect-
ing extracellular matrix (ECM) remodeling, were prominent (14,
29). A number of studies have also provided compelling evidence
supporting the importance of conjunctival inflammation in the
development of scarring and blinding complications (11, 18, 43,
55, 57).
Twomodels have been proposed to account for the pathogenesis
ofC. trachomatis-induced scarring in the eye or genital tract: the “im-
munological” and the “cellular” paradigms,which arenotnecessarily
mutually exclusive (7, 16, 53). The immunological paradigm argues
that cellular immune responses, especially those involving T cells,
against specific chlamydial antigens are important in causing disease.
The cellular paradigm proposes that host epithelial cells act as a key
innate responder cell and are central in driving tissue damage.
In this case-control study we investigated the pathophysiology
of trachomatous conjunctival scarring by measuring conjunctival
gene expression. We examined the hypotheses that conjunctival
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scarring is associated with (i) a predominantly Th2
(interleukin-13 [IL-13] mediated) rather than Th1 response, (ii)
various profibrotic mediators, such as matrix metalloproteinases,
and (iii) markers of innate immunity. In addition, we investigated
the relationship between the expression of these various factors
and both C. trachomatis and other bacterial infections. Finally, we
related the gene expression profile to the microscopic tissue mor-
phology changes and inflammatory cell infiltrate observed by in
vivo confocal microscopy (IVCM). IVCM is a relatively new tech-
nique to examine the ocular surface, which provides high-
resolution images down to the cellular level (31, 32).
MATERIALS AND METHODS
Ethical approval. This study adhered to the tenets of the Declaration of
Helsinki. It was approved by the ethics committees of the Tanzanian Na-
tional Institute for Medical Research, the Kilimanjaro Christian Medical
Centre, and the London School of Hygiene and Tropical Medicine. The
study was explained to potential study subjects and written, informed
consent was obtained before enrollment.
Participant recruitment. The recruitment of participants into this
population-based study has been previously described (30, 32). Briefly,
adults with trachomatous conjunctival scarring, but without trichiasis,
were recruited from an area of trachoma endemicity in the Siha district of
northern Tanzania. Control subjects without scarring from the same
community, frequency matched for ethnicity, were also recruited.
Clinical examination and sample collection. All participants were
examined clinically, as previously described, using the 1981WorldHealth
Organization trachoma grading system with some modifications, includ-
ing a more detailed grading for conjunctival scarring (17, 30, 32). The left
conjunctivawas anesthetizedwith preservative-free proxymetacaine 0.5%
eye drops (Minims; Chauvin Pharmaceuticals) and a swab collected for
microbiological analysis from the inferior fornix. Two upper tarsal con-
junctival swabs were also collected (Dacron polyester-tipped; Hardwood
Products Company, Guildford, ME). The first was for RNA isolation (de-
scribed later) andwas placed directly into a tube containing 0.2ml of RNA
stabilizer (RNAlater; Life Technologies, United Kingdom). The second
was for C. trachomatis detection and put into a dry tube. Samples were
kept on ice packs until frozen later the same day at80°C.
Confocal microscopy assessment. IVCM examination of the upper
tarsal conjunctiva was performed using aHeidelberg Retina Tomograph 3
(HRT3) in combination with the Rostock Corneal Module (RCM)
(Heidelberg Engineering GmbH, Dossenheim, Germany) according to
previously described examination and image grading protocols (31).
IVCM images were graded for inflammatory features and subepithelial
connective tissue organization/scarring (Fig. 1 and 2).
Quantitative RT-PCR. Twenty-three different human gene tran-
scripts were selected for quantitation by real-time reverse transcription-
PCR (RT-PCR), including the following: IFN- (IFNG); indoleamine-
2,3-dioxygenase (INDO); tumor necrosis factor alpha (TNFA);
interleukin-1 (IL1B); interleukin-10 (IL-10); interleukin-12 (IL12B);
interleukin 13 (IL-13); interleukin-13 receptor, alpha 2 (IL13RA2); S100
calcium-binding protein A7 (S100A7); defensin, beta 4A (DEFB4A);
chemokine (C-X-C motif) ligand 5 (CXCL5); serum amyloid A1 (SAA1);
arginase, liver (ARG1); nitric oxide synthase 2, inducible (NOS2); matrix
metalloproteinase 1 (MMP1); matrix metalloproteinase 7 (MMP7); ma-
trixmetalloproteinase 9 (MMP9);matrixmetalloproteinase 10 (MMP10);
matrix metalloproteinase 12 (MMP12); TIMP (tissue inhibitor of matrix
metalloproteinase) matrix metalloproteinase inhibitor 1 (TIMP1); SPARC
(secreted protein, acidic, cysteine-rich)-like 1 (hevin) (SPARCL1); comple-
ment factor H (CFH); and CD83molecule (CD83).
Genes were chosen to investigate the specific hypotheses outlined
above. Specifically, IFNG, IL12B, IL-13, and IL13RA2 expression was used
to investigate a Th1/Th2 predominance; the expression of matrix metal-
loproteinases, TIMP1, and SPARCL1 as potentially important regulators
of extracellular matrix; and IL1B, TNFA, S100A7, DEFB4A, CXCL5, and
SAA1 expression as evidence of a proinflammatory and/or innate immune
response. We were also interested in examining evidence of differential
macrophage activity (ARG1 and NOS2), mature dendritic cells (CD83),
and complement regulation (CFH). The selection of these genes was in-
formed by previous studies, including a conjunctival microarray tran-
scriptome analysis (6, 9, 14, 15, 22, 27, 28, 42, 46, 47–49). The microarray
data have been deposited in NCBI’s Gene Expression Omnibus under
accession numbers GSE23705 (Ethiopia) and GSE24383 (Tanzania).
Total RNA was extracted from the swab sample using an RNeasy mi-
crokit (Qiagen, Hilden, Germany) and reverse transcribed to cDNAusing
the QuantiTect reverse transcription kit (Qiagen) according to the man-
ufacturer’s instructions. Multiplex real-time quantitative PCR was per-
formed on a Rotor-Gene 6000 (Corbett Research, Cambridge, United
Kingdom) using the QuantiTect Multiplex NoROX kit (Qiagen) accord-
ing to the manufacturer’s instructions. Probes and primers for multiplex
assays, which included up to four separate targets (including HPRT-1,
which was used as a reference gene), were designed and synthesized by
Sigma Life Science (www.sigma.com/designmyprobe; available on re-
quest). The samples were tested in duplicate, in a total reaction mixture
volume of 25l, which contained 2l of sample or standard. The thermal
cycle protocol used the following conditions: 95°C for 15min, followed by
45 to 50 cycles of denaturation at 94°C for 30 s and then annealing and
extension at 60°C for 30 s. Fluorescence data was acquired at the end of
each cycle. The relative efficiency of the component reactions was assessed
using standards containing all targets in a sequence of 10-fold serial dilu-
tions.
Microbiology samples and analysis. C. trachomatis DNA was de-
tected using a PCR-based assay (Amplicor CT/NG Test; Roche) with pre-
viously describedmodifications (12). Samples for culture were inoculated
onto blood and chocolate agar later on the day of collection (rarely more
than 6 h) and incubated at 37°C for 48 h. Culture isolates were identified
by standard microbiological techniques.
Data analysis. Data were entered into Access 2007 (Microsoft) and
analyzed using STATA 11.0 (StataCorp LP, TX). The transcript abun-
dances for the genes of interest were standardized relative to that of
HPRT1 in the same reaction mixture using the CT method and were
normalized by log10 transformation (37). Linear regression models were
used to estimate the fold changes (age and sex adjusted) in the levels of
gene expression in those with clinically visible scarring compared to con-
trols, subdivided into those with no/minimal inflammation (TS [inflam-
mation grades P0 and P1]) and those with inflammation (TSI [inflamma-
tion grades P2 and P3]), where P0 is no inflammation, P1 is minimal
inflammation with individual papillae prominent, P2 ismoderate inflam-
mation in which normal vessels appear hazy, and P3 is pronounced in-
flammation in which normal vessels on the tarsus are hidden over more
than half the surface) (17). Similar fold changes were estimated for the
presence of clinically significant inflammation (P2 or P3), adjusted for the
level of clinical scarring as well as age and sex. Age- and sex-adjusted fold
changes in gene expression by grade of IVCM connective tissue organiza-
tion/scarring and for the presence of dendritiform cells were also esti-
mated. Correlation coefficients were estimated between the increase in
gene expression (log10 transformed) and the IVCM inflammatory infil-
trate, with the significance tested using age- and sex-adjusted linear re-
gression models. Likelihood ratio tests were used to assess the strength of
association of each factor with the gene expression fold change. P values
for all associations are shown in Results. For reference, the P values for the
critical significance thresholds determined by a Bonferroni correction for
multiple comparisons are shown in the table footnotes. However, the
choice of targets for gene expression was not selected at random, as is
assumed by the Bonferroni method, but contain related groups of genes
which might be expected to act in a similar manner. In addition, using
such a conservative correction increases the likelihood of a type 2 error.
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RESULTS
Study participants. We recruited 363 cases with trachomatous
conjunctival scarring and 363 control participants without
scarring. The demographic, clinical, IVCM, and nonchlamyd-
ial bacterial infection data have previously been reported in
detail (30, 32). In summary, controls were younger than the
cases (mean 31.9 versus 50.3 years, P 0.001), and all analyses
were age and sex adjusted. Conjunctival scarring in the cases
was mostly mild to moderate and cases had significantly more
clinical inflammation than controls. IVCM analysis showed
that the cases had more inflammatory cells and a higher con-
nective tissue scarring score. Nonchlamydial pathogenic or-
ganisms were cultured more frequently from cases (25 [6.9%])
than from controls (7 [1.9%], P 0.002). The most frequently
cultured pathogenic organisms were Haemophilus influenzae
type b and Streptococcus pneumoniae, while coagulase-negative
staphylococci, Corynebacterium spp., Streptococcus viridans,
and Bacillus spp. were designated as commensal organisms in
this analysis. Five (1.4%) of the cases and none of the controls
had C. trachomatis infection detected.
Conjunctival gene expression. Quantitative, real-time RT-
PCRwas performed for 23 gene expression targets for all 363 cases
and 363 controls. There was inadequate sample for detection in
four samples (three cases and one control), and amplification
failed in a number of experiments for technical reasons related to
laboratory power supply problems. The number of samples suc-
FIG1 In vivo confocalmicroscopy grading systemof inflammatory features. Images are 400 by 400m. (A) Inflammatory infiltrate: seen asmultiple brightwhite
nuclei. The mean inflammatory cell density of three randomly selected volume scans is calculated using the HRT/RCM software. The individual scan with the
highest density of cells from within the volume scan is used for inflammatory cell density counting. (B) Dendritiform cells: graded as present or absent. To be
present, the mean number of DCs per volume scan needs to be1. The largest number of dendritiform cells in any individual scan in a volume scan is used for
measurement. A mean number of1 is used to differentiate occasional dendritiform cells seen in scans of otherwise normal subjects. (C) Tissue edema: seen as
multiple black empty spaces. Graded as present or absent in any volume scan. (D) Papillae: seen as elevations with a central vascular network. Graded as present
or absent in any volume scan.
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cessfully detected for each target ranged from 313 to 359 for cases
and 316 to 362 for controls.
Gene expression levels in relation to clinical findings. Cases
with scarring had enriched gene expression compared to controls for
themajority of transcriptsmeasured, even after adjusting for age and
sex (Table 1). This tended to be more marked in those cases with
inflammation (increased: INDO, TNFA, IL1B, S100A7, DEFB4A,
CXCL5, SAA1, ARG, NOS2, MMP7, MMP9, MMP12, TIMP1, and
CD83; decreased: MMP10, CFH, and SPARCL1). There was also
some evidence, but with less robust P values, that the expression of
IFNG and IL13RA2were increased in cases with scarring.
After adjusting for age, sex, and the level of clinical scarring, a
number of genes were also differentially expressed in those with
clinical inflammation compared to those without inflammation
(increased: INDO, IL1B, DEFB4A, CXCL5, MMP7, MMP9,
MMP12, and CD83; decreased:MMP10, SPARCL1, and CFH).
Gene expression in relation to IVCM findings. The relation-
ships between the gene expression results and the IVCM findings
are presented in Table 2. Increasing IVCMconnective tissue grade
was associated with increased expression of S100A7 (which also
had the largest fold changes), TIMP1, and CFH and with de-
creased expression of SPARCL1. There was also some evidence,
but with less-robust P values, that the connective tissue grade was
associated with increased levels of INDO, IL1B, SAA1, ARG1,
MMP12, and CD83.
The expression of a number of genes was correlated with the
IVCM inflammatory infiltrate density. The correlation coeffi-
cient for IL1B, S100A7, and DEFB4 was greater than 0.40
FIG 2 In vivo confocal microscopy grading system for conjunctival connective tissue organization. Images are 400 by 400 m. (A) Normal: homogenous,
amorphous appearance, with occasional, fine, wispy strands. (B) Grade 1: heterogenous appearance with poorly defined clumps or bands present. (C) Grade 2:
clearly defined bands of tissue which constitute less than 50% of the area of the scan. (D) Grade 3: clearly defined bands or sheets of tissue which constitute 50%
or more of the area of the scan and in which striations are present. If different grades of scarring are seen within a particular volume scan then the highest grade
is recorded. The connective tissue which is graded needs to be separate from that associated with the vascular tissue; if this is not possible then the scan is
considered ungradable.
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(Fig. 3). For SAA1, MMP9, and MMP12 it was between 0.25
and 0.35, and for MMP10 and SPARCL1 it was between
0.20 and 0.30. The presence of DFCs was associated with
increased expression of INDO and S100A7 and with decreased
expression of SPARCL1.
Gene expression levels in relation to microbiology findings.
Infection with C. trachomatis was associated with upregulated
IFNG, INDO, and NOS2 and with downregulated MMP10 and
SPARCL1 (Table 3; note that only five participants had detectable
C. trachomatis DNA). There was also some evidence, but with
less-robust P values, that C. trachomatis infection was associated
with increased IL12B,MMP1,MMP7, andMMP10. Nonchlamyd-
ial bacterial infection was associated with increased expression of
INDO, S100A7,DEFB4A, andMMP12 andwith decreased expres-
sion of MMP10, SPARCL1, and CFH (Table 3). There was also
some evidence that nonchlamydial bacterial infection was associ-
ated with increased IL1B, IL-10, CXCL5, SAA1, MMP7, and
MMP9.
IVCM findings in relation to nonchlamydial bacterial infec-
tion status. A new combined analysis of previously published
IVCM and microbiology data found that pathogenic organisms
were associated with significantly more inflammatory cells (P 
0.0006) and with the presence of tissue edema (P 0.02) (Table 4)
(30, 32).
DISCUSSION
Previous studies have used gene expression measurement of con-
junctival swab samples to study the pathogenesis of trachoma (6,
9, 14, 21, 22, 29, 46). However, this is the first study to systemati-
cally compare a large number of cases with trachomatous scarring
and control subjects in which the scarring had not yet progressed
to trichiasis. Cases with trichiasis are quite distinct from cases with
scarring alone since they have a persistent foreign body abrading
the globe stimulating inflammation and facilitating secondary in-
fection (13). In the present study we have shown that scarring
without trichiasis is associated with large fold changes in gene
expression of various cytokines, chemokines, and other immuno-
fibrogenicmediators, even though the scarring was generally mild
to moderate.
We found that mild to moderate trachomatous scarring is
strongly associated with a proinflammatory, innate immune re-
sponse, which has marked antimicrobial properties, with in-
creased expression of S100A7,DEFB4A,CXCL5, IL1B, TNFA, and
SAA1. This is consistent with a transcriptomemicroarray study of
end-stage scarring trachomawith trichiasis from Ethiopia (14). In
both studies the expression of S100A7 (psoriasin) showed the
greatest fold increase between cases and controls. Psoriasin was
initially identified as being upregulated in epithelial cells from
psoriatic lesions (38). It is an antimicrobial peptide (AMP) and
TABLE 1 Conjunctival gene expression in relation to clinical phenotypea
Geneb
TSI vs C TS vs C Inflamed vs noninflamed
FC P FC P FC P
S100A7 5.54 0.0001 3.2 0.0001 1.3 0.11
SAA1 4.99 0.0001 2.11 0.0001 1.6 0.04
DEFB4A 4.72 0.0001 1.42 0.01 2.46 0.0001
CXCL5 3.89 0.0001 1.18 0.43 3.4 0.0001
MMP12 3.55 0.0001 1.74 0.0001 1.62 0.0002
INDO 3.29 0.0001 1.5 0.0001 1.96 0.0001
MMP9 3.06 0.0001 1.76 0.0001 1.67 0.0001
IL1B 2.57 0.0001 1.59 0.0001 1.48 0.0003
NOS2 2.16 0.0001 1.27 0.005 1.38 0.007
MMP7 2.14 0.0001 1.23 0.003 1.51 0.0001
CD83 1.9 0.0001 1.4 0.0001 1.31 0.0004
IL13RA2 1.62 0.006 1.38 0.008 1.08 0.65
IL12B 1.52 0.02 1.29 0.04 1.22 0.23
TNFA 1.47 0.0001 1.14 0.008 1.23 0.003
IL-10 1.46 0.2 0.64 0.03 1.27 0.42
TIMP1 1.46 0.0001 1.4 0.0001 0.93 0.3
IFNG 1.42 0.001 1.06 0.4 1.41 0.002
ARG1 1.3 0.01 1.25 0.0003 1.04 0.64
IL-13 1.22 0.3 1.17 0.19 1.09 0.64
CFH 0.75 0.0001 1.13 0.005 0.68 0.0001
MMP1 0.58 0.009 1.28 0.05 0.63 0.02
MMP10 0.38 0.0001 0.86 0.02 0.54 0.0001
SPARCL1 0.06 0.0001 0.51 0.0001 0.19 0.0001
a TSI versus C and TS versus C values were adjusted for age and sex. Inflamed versus noninflamed values were adjusted for age, sex, and level of clinical scarring. Using a Bonferroni
correction for 69 comparisons, a P value of0.0007 would be considered significant. See the text for discussion. TSI, trachomatous scarring with inflammation; TS, trachomatous
scarring without inflammation; FC, fold change.
b S100A7 S100 calcium binding protein A7; SAA1 serum amyloid A1; DEFB4A defensin, beta 4A; CXCL5 chemokine (C-X-C motif) ligand 5;MMP12matrix
metalloproteinase 12; INDO indoleamine-2,3-dioxygenase;MMP9matrix metalloproteinase 9; IL1B interleukin-1; NOS2 nitric oxide synthase 2, inducible;MMP7
matrix metalloproteinase 7; CD83 CD83 molecule; IL13RA2 interleukin 13 receptor, alpha 2; IL12B interleukin-12; TNFA tumor necrosis factor, alpha/beta; IL-10
interleukin 10; TIMP1 TIMP (tissue inhibitor of matrix metalloproteinase) matrix metalloproteinase inhibitor 1; IFNG interferon gamma; ARG1 arginase, liver;
IL-13 interleukin-13; CFH complement factor H;MMP1matrix metalloproteinase 1;MMP10matrix metalloproteinase 10; SPARCL1 SPARC (secreted protein, acidic,
cysteine-rich)-like 1 (hevin).
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TABLE 2 Gene expression levels in relation to in vivo confocal microscopy findingsa
Gene
FC in gene expression with increasing
connective tissue grade
IVCM infiltrate
FC in gene expression if
dendritiform cells are
present
Grade FC P CC P FC P
S100A7 1 1.00 0.0001 0.43 0.0001 2.03 0.0004
2 1.64
3 3.76
SAA1 1 1.00 0.002 0.28 0.0001 1.80 0.03
2 1.18
3 2.74
DEFB4A 1 1.00 0.01 0.42 0.0001 1.74 0.01
2 0.84
3 1.60
CXCL5 1 1.00 0.50 0.08 0.01 1.51 0.22
2 1.25
3 1.40
MMP12 1 1.00 0.004 0.31 0.0001 1.36 0.05
2 1.23
3 1.69
INDO 1 1.00 0.004 0.16 0.0001 1.71 0.0001
2 1.17
3 1.60
MMP9 1 1.00 0.01 0.28 0.0001 1.19 0.19
2 1.26
3 1.33
IL1B 1 1.00 0.008 0.49 0.0001 1.15 0.27
2 1.18
3 1.45
NOS2 1 1.00 0.14 0.15 0.02 1.28 0.07
2 1.01
3 1.33
MMP7 1 1.00 0.65 0.08 0.14 1.06 0.62
2 1.02
3 1.12
CD83 1 1.00 0.003 0.10 0.03 1.11 0.25
2 1.21
3 1.13
IL13RA2 1 1.00 0.79 0.14 0.005 0.92 0.65
2 0.98
3 1.11
IL12B 1 1.00 0.87 –0.09 0.01 0.90 0.59
2 1.06
3 1.07
TNFA 1 1.00 0.39 0.12 0.009 1.05 0.54
2 1.07
3 1.04
Continued on following page
Hu et al.
126 iai.asm.org Infection and Immunity
therefore an important component of innate immune defense
(56). Psoriasin is chemotactic for neutrophils and regulates neu-
trophil function by inducing the production of several cytokines,
chemokines, and reactive oxygen species (34, 61). It has been
shown to reduce Escherichia coli survival, themechanism of which
may be either through zinc sequestration or direct adherence with
the bacteria (24, 36). It has more recently been shown to be up-
regulated at the ocular surface in response to Staphylococcus au-
reus and Haemophilus influenzae (23). Binding of E. coli flagellin
by the Toll-like receptor 5 on keratinocytes is important in pso-
riasin induction, supporting its role as an innate immune mole-
cule (2). The defensins are another group of AMPs found at the
ocular surface, with -defensins released by leukocytes and epi-
thelial cells (26, 41). CXCL5 is a potent chemotaxin involved in
neutrophil activation which is produced by epithelial cells (33,
56). Tumor necrosis factor alpha (TNF-) and IL-1 are proin-
flammatory mediators which play a central role in mediating an
innate immune response and have previously been found to be
associated with active and scarring trachoma (3, 6, 9, 15, 22, 47).
Serum amyloid A, of which SAA1 is a main isoform, is an acute-
phase protein which is raised in inflammatory diseases and has
been shown to have antibacterial effects (19, 39).
Theupregulationof these variousproinflammatory, chemotactic,
andantimicrobialmediators suggests an important role for the innate
immune response in trachomatous scarring. This is consistent with
the cellular paradigm of Chlamydia trachomatis pathogenesis. While
therewas someevidenceofTh1 response in scarring (increased IFNG
and INDO expression), there was no significant difference in IL-13
expression, which might have suggested a Th2 response. There was
some evidence that the expression of IL13RA2, which appears to act
as a decoy receptor for IL-13 and opposes its function, was increased
in cases compared to controls (60).
Many of the measured transcripts were upregulated in the
presence of clinical inflammation. When scarred cases were com-
pared to controls without scarring, the additional presence of in-
flammation in the cases tended to lead to more marked increases
in gene expression. These observations are consistent with the
hypothesis that episodes of inflammation are important in the
TABLE 2 (Continued)
Gene
FC in gene expression with increasing
connective tissue grade
IVCM infiltrate
FC in gene expression if
dendritiform cells are
present
Grade FC P CC P FC P
IL-10 1 1.00 0.15 0.13 0.0003 1.11 0.77
2 0.86
3 0.49
TIMP1 1 1.00 0.0001 0.19 0.0005 1.09 0.27
2 1.18
3 1.46
IFNG 1 1.00 0.43 –0.12 0.0003 1.05 0.71
2 0.91
3 0.89
ARG 1 1.00 0.003 0.14 0.002 1.09 0.42
2 1.24
3 1.17
IL-13 1 1.00 0.13 0.001 0.98 0.92 0.27
2 1.24
3 0.94
CFH 1 1.00 0.0004 –0.09 0.004 0.93 0.30
2 1.15
3 1.24
MMP1 1 1.00 0.32 0.02 0.88 0.97 0.87
2 1.06
3 1.40
MMP10 1 1.00 0.02 –0.22 0.0001 0.76 0.01
2 1.14
3 0.85
SPARCL1 1 1.00 0.0001 –0.27 0.0001 0.30 0.0001
2 0.87
3 0.67
a Fold change (FC) values were adjusted for age and sex. Using a Bonferroni correction for 69 comparisons, a P value of0.0007 would be considered significant. See the text for
further discussion. IVCM, in vivo confocal microscopy; CC, correlation coefficient. See Table 1 for gene abbreviations.
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pathogenesis of scarring and blindness. It is also interesting that a
number of genes, for example, S100A7, IL1B, SAA1, andMMP12,
showed large fold changes in gene expression even in relatively
noninflamed cases with scarring compared to controls. These
genes also showed a clearly progressive increase in expressionwith
increasing IVCM connective tissue organization grade.
We found infection with C. trachomatis to be infrequent in
these adults with conjunctival scarring, with a similar detection
rate to previous studies of trachomatous trichiasis (8, 11, 13).
While caution is needed in interpreting these data because of the
small numbers, individuals infected with C. trachomatis had gene
expression profiles characteristic of C. trachomatis infection in
children (9, 46). There was a typical Th1-dominated response,
with upregulated IFNG and IL12B (P 0.05) and also INDO and
NOS2 (both IFN- regulated) and some acute-phase reactants.
Infection with other bacteria was more frequent, and many of the
genes described above involved in innate immunity showedmod-
erate to large increases in expression if a pathogenic organismwas
present. A previous study found that the presence of bacterial
infection was associated with increased expression of IL1B,
TNF-, MMP1, MMP9, and TIMP2 after trichiasis surgery (10).
In the present study, bacterial infection was also found to be asso-
ciated with an increased inflammatory infiltrate and tissue edema
with IVCM. Overall, these studies support the hypothesis that
nonchlamydial bacterial infection is important in driving the scar-
ring process.
Matrixmetalloproteinases are capable of degrading the protein
components of the ECM and also have wide-ranging effects on
inflammatory and immune responses (50, 58). Previous studies
have implicatedMMPs in the pathogenesis of trachomatous scar-
ring, and this was further confirmed in the present study in a
separate population (9, 10, 14, 20, 29, 44). MMP7, MMP9,
MMP12, and TIMP1were upregulated in scarring and inflamma-
tion, whereas MMP10 and SPARCL1 were downregulated.
SPARCL1 is a matricellular protein, which regulates the synthesis
TABLE 3 Gene expression in relation to microbiological infection
statusa
Gene
Chlamydial infection
Nonchlamydial
bacterial infection
FC P FCb P
S100A7 4.21 0.04 2.59 0.0006
SAA1 8.06 0.01 2.47 0.008
DEFB4A 4.82 0.02 3.56 0.0001
CXCL5 8.2 0.07 4.15 0.002
MMP12 1.84 0.21 2.21 0.0001
INDO 6.78 0.0001 2.74 0.0001
MMP9 1.57 0.28 1.73 0.002
IL1B 1.49 0.32 1.72 0.001
NOS2 4.5 0.0003 1.40 0.06
MMP7 3.01 0.002 1.52 0.003
CD83 1.30 0.34 1.27 0.05
IL13RA2 0.81 0.72 0.98 0.94
IL12B 3.10 0.05 1.16 0.56
TNFA 1.60 0.06 1.14 0.20
IL-10 1.29 0.81 3.30 0.005
TIMP1 0.98 0.94 1.09 0.36
IFNG 4.2 0.0001 1.12 0.46
ARG 0.71 0.27 0.92 0.56
IL-13 0.26 0.02 0.66 0.13
CFH 0.64 0.03 0.67 0.0001
MMP1 0.14 0.004 0.59 0.06
MMP10 0.34 0.002 0.46 0.0001
SPARCL1 0.02 0.0001 0.09 0.0001
a Fold change (FC) values were adjusted for age and sex. Using a Bonferroni correction
for 46 comparisons, a P value of0.001 would be considered significant. See the text
for further discussion. See Table 1 for gene abbreviations.
b Compared to no organism cultured.
FIG3 Gene expression levels relative toHPRT1 of S100A7,DEFB4A, and IL1B
by in vivo confocal microscopy inflammatory cell infiltrate.
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and turnover of the ECM (35, 54). The gene expression levels by
clinical scarring grade were broadly consistent with the levels by
IVCM connective tissue grade, and the expression levels by clini-
cal inflammation were consistent with the IVCM inflammatory
infiltrate correlation. The differential gene expression of these
ECM modifiers was closely related to bacterial infection status as
discussed above.
Strengths of this population-based study were that we studied
a large number of cases with early scarring trachoma to analyze
gene expression changes in relation to the clinical, IVCM, and
microbiological status. There are, however, a number of limita-
tions. Gene expression levels do not necessarily reflect the level of
functional protein, exemplified by transforming growth factor ,
which has significant posttranscriptional regulation. Conjunctival
swabs obtain material from the tissue surface and so have a ten-
dency to limit the observations to events in or near the epithelium.
To address these two issues, we are currently comparing gene ex-
pression with immunohistochemical analysis of conjunctival bi-
opsy tissue.
This study showed that mild to moderate trachomatous scar-
ring is strongly associated with a proinflammatory, innate im-
mune response and with differential expression of various modi-
fiers of the ECM. We found no evidence for an active role for
IL-13/Th2 responses at this stage of the disease. This is consistent
with the findings from a microarray transcriptome study from
Ethiopia on advanced trachomatous scarring (14). We were also
able to use IVCM to show differential transcript levels according
to connective tissue morphology and inflammatory cell infiltrate.
A key determinant in the expression of many of these genes ap-
pears to be the presence of nonchlamydial bacterial infection
which, as well as causing inflammation, may contribute to the
scarring process.
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